Literature DB >> 6546476

Long-term follow-up of patients with Grave's disease treated by subtotal thyroidectomy.

W P Maier, B M Derrick, A D Marks, B J Channick, F C Au, H T Caswell.   

Abstract

This long-term follow-up study of 83 patients with Grave's disease who were treated by subtotal thyroidectomy reemphasizes the fact that postoperative hypothyroidism occurs primarily in the first postoperative year (27 percent of the study patients). In addition, there was no evidence of progressive increase in the incidence of hypothyroidism in subsequent years. Patients treated with radioactive iodine have a reported incidence of hypothyroidism of 70 percent 10 years postoperatively [4]. The 6 percent incidence of recurrent hyperthyroidism is much less than a reported incidence of 90 percent in patients treated with long-term antithyroid drugs [7]. Subtotal thyroidectomy continues to be an excellent method of treatment for patients with Grave's disease and compared favorably with both radioactive iodine and long-term antithyroid drugs.

Entities:  

Mesh:

Year:  1984        PMID: 6546476     DOI: 10.1016/0002-9610(84)90104-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease.

Authors:  Y Mori; N Matoba; S Miura; N Sakai; Y Taira
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

2.  The influence of remnant size, antithyroid antibodies, thyroid morphology, and lymphocyte infiltration on thyroid function after subtotal resection for hyperthyroidism.

Authors:  E Jörtsö; S Lennquist; B Lundström; K Norrby; S Smeds
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

3.  A new method of subtotal thyroidectomy for Graves' disease leaving a unilateral remnant based on the upper pole.

Authors:  Yu Liu; Bin Liu; Rui-Lei Liu; Hua Jiang; Ze-Nan Huang; Yong Huang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.